BIOMAT Database Logo BIOMAT Database Logo

Germline and somatic mutations of the RET proto-oncogene in apparently sporadic medullary thyroid carcinomas. 1998

C Scurini, and L Quadro, and O Fattoruso, and U Verga, and A Libroia, and G Lupoli, and E Cascone, and L Marzano, and S Paracchi, and B Busnardo, and M E Girelli, and A Bellastella, and V Colantuoni
Istituto di Endocrinologia, Facoltà di Medicina, Seconda Università di Napoli, Italy.

Medullary thyroid carcinomas (MTC) occur sporadically or as part of inherited multiple endocrine neoplasia (MEN) type 2 syndromes. To recognize misdiagnosed familial cases and to establish the frequency of somatic mutations, a series of 50 patients, clinically diagnosed with sporadic MTC, were analyzed for mutations in the RET proto-oncogene. The clinical management of the patient and of the family is different in the two cases. Germline mutations were detected in three independent cases, demonstrating that they were associated to familial MTC. The mutations affected exon 11 in two cases and exon 14 in one case. Somatic mutations were detected in eight patients (30%) and they were indicative of sporadic MTC. In seven cases the mutation affected codon 918 of exon 16 and in one case codon 634 in exon 11. No RET mutations were detected in the remaining patients. A different genetic and clinical management is proposed for individuals with a diagnosis of familial or sporadic MTC.

UI MeSH Term Description Entries
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D011518 Proto-Oncogene Proteins Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity. Cellular Proto-Oncogene Proteins,c-onc Proteins,Proto Oncogene Proteins, Cellular,Proto-Oncogene Products, Cellular,Cellular Proto Oncogene Proteins,Cellular Proto-Oncogene Products,Proto Oncogene Products, Cellular,Proto Oncogene Proteins,Proto-Oncogene Proteins, Cellular,c onc Proteins
D011519 Proto-Oncogenes Normal cellular genes homologous to viral oncogenes. The products of proto-oncogenes are important regulators of biological processes and appear to be involved in the events that serve to maintain the ordered procession through the cell cycle. Proto-oncogenes have names of the form c-onc. Proto-Oncogene,Proto Oncogene,Proto Oncogenes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000090063 Proto-Oncogene Mas A protein that is encoded by the MAS1 gene. It is a receptor for ANGIOTENSIN 1-7 and acts as an antagonist of ANGIOTENSIN-2 TYPE 1 RECEPTOR. C-Mas Protein,II-Proto-Oncogene Proteins, Cellular,Mas Protein,Mas1 Protein,Proto-Oncogene Protein Mas,Proto-Oncogene Proteins C-Mas-1,C Mas Protein,C-Mas-1, Proto-Oncogene Proteins,Cellular II-Proto-Oncogene Proteins,II Proto Oncogene Proteins, Cellular,Mas, Proto-Oncogene,Protein Mas, Proto-Oncogene,Protein, C-Mas,Protein, Mas,Protein, Mas1,Proteins, Cellular II-Proto-Oncogene,Proto Oncogene Mas,Proto Oncogene Proteins C Mas 1
D013964 Thyroid Neoplasms Tumors or cancer of the THYROID GLAND. Cancer of Thyroid,Thyroid Cancer,Cancer of the Thyroid,Neoplasms, Thyroid,Thyroid Adenoma,Thyroid Carcinoma,Adenoma, Thyroid,Adenomas, Thyroid,Cancer, Thyroid,Cancers, Thyroid,Carcinoma, Thyroid,Carcinomas, Thyroid,Neoplasm, Thyroid,Thyroid Adenomas,Thyroid Cancers,Thyroid Carcinomas,Thyroid Neoplasm
D051096 Proto-Oncogene Proteins c-ret Receptor protein-tyrosine kinases involved in the signaling of GLIAL CELL-LINE DERIVED NEUROTROPHIC FACTOR ligands. They contain an extracellular cadherin domain and form a receptor complexes with GDNF RECEPTORS. Mutations in ret protein are responsible for HIRSCHSPRUNG DISEASE and MULTIPLE ENDOCRINE NEOPLASIA TYPE 2. c-ret Protein,ret Proto-Oncogene Proteins,Proto-Oncogene Protein Ret,Proto-Oncogene Protein c-ret,Receptor Tyrosine Kinase RET,Proto Oncogene Protein Ret,Proto Oncogene Protein c ret,Proto Oncogene Proteins c ret,Proto-Oncogene Proteins, ret,Ret, Proto-Oncogene Protein,c-ret, Proto-Oncogene Protein,c-ret, Proto-Oncogene Proteins,ret Proto Oncogene Proteins
D018095 Germ-Line Mutation Any detectable and heritable alteration in the lineage of germ cells. Mutations in these cells (i.e., "generative" cells ancestral to the gametes) are transmitted to progeny while those in somatic cells are not. Mutation, Germ-Line,Germline Mutation,Germ Line Mutation,Germ-Line Mutations,Germline Mutations,Mutation, Germ Line,Mutation, Germline,Mutations, Germ-Line,Mutations, Germline
D018276 Carcinoma, Medullary A carcinoma composed mainly of epithelial elements with little or no stroma. Medullary carcinomas of the breast constitute 5%-7% of all mammary carcinomas; medullary carcinomas of the thyroid comprise 3%-10% of all thyroid malignancies. (From Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1141; Segen, Dictionary of Modern Medicine, 1992) Carcinomas, Medullary,Medullary Carcinoma,Medullary Carcinomas
D018813 Multiple Endocrine Neoplasia Type 2a A form of multiple endocrine neoplasia characterized by the presence of medullary carcinoma (CARCINOMA, MEDULLARY) of the THYROID GLAND, and usually with the co-occurrence of PHEOCHROMOCYTOMA, producing CALCITONIN and ADRENALINE, respectively. Less frequently, it can occur with hyperplasia or adenoma of the PARATHYROID GLANDS. This disease is due to gain-of-function mutations of the MEN2 gene on CHROMOSOME 10 (Locus: 10q11.2), also known as the RET proto-oncogene that encodes a RECEPTOR PROTEIN-TYROSINE KINASE. It is an autosomal dominant inherited disease. MEN 2,MEN 2a,Neoplasia, Multiple Endocrine Type 2a,Neoplasms, Multiple Endocrine Type 2a,Sipple Syndrome,MEA 2a,MEA II,MEA IIa,MEN II,MEN IIa,MEN-2A Syndrome,MEN2a,Multiple Endocrine Neoplasia Type 2,Multiple Endocrine Neoplasia, Type IIa,Multiple Endocrine Neoplasms Type 2a,Pheochromocytoma And Amyloid-Producing Medullary Thyroid Carcinoma,MEN 2A Syndrome,MEN-2A Syndromes,Pheochromocytoma And Amyloid Producing Medullary Thyroid Carcinoma

Related Publications

C Scurini, and L Quadro, and O Fattoruso, and U Verga, and A Libroia, and G Lupoli, and E Cascone, and L Marzano, and S Paracchi, and B Busnardo, and M E Girelli, and A Bellastella, and V Colantuoni
Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinomas.
March 2008, Molecular and cellular endocrinology,
C Scurini, and L Quadro, and O Fattoruso, and U Verga, and A Libroia, and G Lupoli, and E Cascone, and L Marzano, and S Paracchi, and B Busnardo, and M E Girelli, and A Bellastella, and V Colantuoni
Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma.
March 1996, Clinical endocrinology,
C Scurini, and L Quadro, and O Fattoruso, and U Verga, and A Libroia, and G Lupoli, and E Cascone, and L Marzano, and S Paracchi, and B Busnardo, and M E Girelli, and A Bellastella, and V Colantuoni
Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma.
July 1995, Clinical endocrinology,
C Scurini, and L Quadro, and O Fattoruso, and U Verga, and A Libroia, and G Lupoli, and E Cascone, and L Marzano, and S Paracchi, and B Busnardo, and M E Girelli, and A Bellastella, and V Colantuoni
[Proto-oncogene RET somatic mutations in medullary thyroid carcinoma].
January 2001, Wiadomosci lekarskie (Warsaw, Poland : 1960),
C Scurini, and L Quadro, and O Fattoruso, and U Verga, and A Libroia, and G Lupoli, and E Cascone, and L Marzano, and S Paracchi, and B Busnardo, and M E Girelli, and A Bellastella, and V Colantuoni
Ret proto-oncogene mutations in apparently sporadic Turkish medullary thyroid carcinoma patients: Turkmen study.
October 2005, Journal of endocrinological investigation,
C Scurini, and L Quadro, and O Fattoruso, and U Verga, and A Libroia, and G Lupoli, and E Cascone, and L Marzano, and S Paracchi, and B Busnardo, and M E Girelli, and A Bellastella, and V Colantuoni
RET proto-oncogene mutations in inherited and sporadic medullary thyroid cancer.
October 1994, Human molecular genetics,
C Scurini, and L Quadro, and O Fattoruso, and U Verga, and A Libroia, and G Lupoli, and E Cascone, and L Marzano, and S Paracchi, and B Busnardo, and M E Girelli, and A Bellastella, and V Colantuoni
Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma.
October 1996, The Journal of clinical endocrinology and metabolism,
C Scurini, and L Quadro, and O Fattoruso, and U Verga, and A Libroia, and G Lupoli, and E Cascone, and L Marzano, and S Paracchi, and B Busnardo, and M E Girelli, and A Bellastella, and V Colantuoni
[Germline mutations of the ret proto-oncogene in Chilean patients with hereditary and sporadic medullary thyroid carcinoma].
July 2001, Revista medica de Chile,
C Scurini, and L Quadro, and O Fattoruso, and U Verga, and A Libroia, and G Lupoli, and E Cascone, and L Marzano, and S Paracchi, and B Busnardo, and M E Girelli, and A Bellastella, and V Colantuoni
New multiple somatic mutations in the RET proto-oncogene associated with a sporadic medullary thyroid carcinoma.
March 2006, Thyroid : official journal of the American Thyroid Association,
C Scurini, and L Quadro, and O Fattoruso, and U Verga, and A Libroia, and G Lupoli, and E Cascone, and L Marzano, and S Paracchi, and B Busnardo, and M E Girelli, and A Bellastella, and V Colantuoni
Mutations of codon 918 in the RET proto-oncogene correlate to poor prognosis in sporadic medullary thyroid carcinomas.
October 1995, The Journal of clinical endocrinology and metabolism,
Copied contents to your clipboard!